June 11, 2010Congestive Heart Failure
Digoxin Use and Heart Failure Outcomes: Results from the Valsartan Heart Failure Trial (Val‐HeFT)
Why the study?
Does digoxin therapy improve outcomes in patients with heart failure?
Population
5,010 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT)
Comparison
Baseline digoxin therapy vs No baseline digoxin therapy
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Digoxin use was associated with higher adjusted risks; hypothesis-generating and should not change practice without randomized confirmation.
Structured PICO
Does digoxin therapy improve outcomes in patients with heart failure?
P
Population
5,010 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT)
I
Intervention
Baseline digoxin therapy
C
Comparator
No baseline digoxin therapy
O
Outcome
All-cause mortality, first morbid event, and heart failure hospitalizationshard clinical
In a retrospective analysis of the Val-HeFT trial, baseline digoxin use was associated with increased risks of all-cause mortality, first morbid event, and heart failure hospitalization, underscoring the need to reassess its role in contemporary heart failure management.
Cite This Study
Butler et al. (2010) studied this question.